Twelve-month positive outcomes of Zephyr endobronchial valves in severe emphysema patients:  LIBERATE trial

D. Slebos (Groningen, Netherlands), S. Wright (Phoenix, United States of America), R. Sue (Phoenix, United States of America), M. Dransfield (Birmingham, United States of America), H. Rivas-Perez (Louisville, United States of America), T. Wiese (Louisville, United States of America), F. Sciurba (Pittsburgh, United States of America), P. Shah (London, United Kingdom), M. Wahidi (Durham, United States of America), H. De Oliviera (Porto Alegre, Brazil), B. Morrissey (Sacramento, United States of America), P. Cardoso (Sao Paulo, Brazil), S. Hays (San Francisco, United States of America), A. Majid (Boston, United States of America), N. Pastis (Charleston, United States of America), L. Kopas (Houston, United States of America), M. Vollenweider (Orlando, United States of America), P. Mcfadden (Los Angeles, United States of America), M. Machuzak (Cleveland, United States of America), D. Hsia (Torrance, United States of America), A. Sung (Palo Alto, United States of America), N. Jarad (Bristol, United Kingdom), M. Kornaszewska (Cardiff, United Kingdom), S. Hazelrigg (Springfield, United States of America), G. Krishna (Mountain View, United States of America), N. Ten Hacken (Groningen, Netherlands), N. Shargill (Redwood City, United States of America), G. Criner (Philadelphia, United States of America)

Source: International Congress 2018 – Interventional pulmonology highlights in 2018: ELVR, TLD and BT
Session: Interventional pulmonology highlights in 2018: ELVR, TLD and BT
Session type: Oral Presentation
Number: 4932
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Slebos (Groningen, Netherlands), S. Wright (Phoenix, United States of America), R. Sue (Phoenix, United States of America), M. Dransfield (Birmingham, United States of America), H. Rivas-Perez (Louisville, United States of America), T. Wiese (Louisville, United States of America), F. Sciurba (Pittsburgh, United States of America), P. Shah (London, United Kingdom), M. Wahidi (Durham, United States of America), H. De Oliviera (Porto Alegre, Brazil), B. Morrissey (Sacramento, United States of America), P. Cardoso (Sao Paulo, Brazil), S. Hays (San Francisco, United States of America), A. Majid (Boston, United States of America), N. Pastis (Charleston, United States of America), L. Kopas (Houston, United States of America), M. Vollenweider (Orlando, United States of America), P. Mcfadden (Los Angeles, United States of America), M. Machuzak (Cleveland, United States of America), D. Hsia (Torrance, United States of America), A. Sung (Palo Alto, United States of America), N. Jarad (Bristol, United Kingdom), M. Kornaszewska (Cardiff, United Kingdom), S. Hazelrigg (Springfield, United States of America), G. Krishna (Mountain View, United States of America), N. Ten Hacken (Groningen, Netherlands), N. Shargill (Redwood City, United States of America), G. Criner (Philadelphia, United States of America). Twelve-month positive outcomes of Zephyr endobronchial valves in severe emphysema patients:  LIBERATE trial. 4932

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: